[A25-15] Sodium thiosulfate (prevention of ototoxicity induced by cisplatin chemotherapy in solid tumours) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2025
Project no.:
A25-15
Commission:
Commission awarded on 03.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Patients 1 month to < 18 years of age with localized, non-metastatic, solid tumours with indication for the prevention of ototoxicity induced by cisplatin chemotherapy
- Patients with hepatoblastoma: hint of minor added benefit
- Patients with other solid tumours: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-15